Federal prisons must offer addiction treatment to pregnant women
H.R. 9756 — MAT Act of 2026 · Filed by John McGuire (R-VA) · Introduced Jul 16, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the federal Bureau of Prisons to offer medication-assisted treatment (MAT) for opioid addiction to all pregnant women in federal custody, with an exception allowing mentally competent women to refuse it. The bill aims to protect fetal health and maternal recovery by ensuring access to evidence-based addiction treatment during pregnancy.
Why we flagged it
The bill is a straightforward directive to a federal agency to provide a specific medical service to a vulnerable population. It is a public health measure, not a market intervention or commemorative act.
What the text implies
- Implementation may require BOP to contract with external providers or expand in-house medical capacity, potentially increasing federal prison healthcare costs.
- The bill does not specify funding mechanism or appropriations, leaving implementation dependent on BOP budget allocation decisions.
The full analysis lists 3 implications of this text.
Who stands to gain
pharmaceutical manufacturers (buprenorphine, methadone suppliers); healthcare providers contracted by BOP for MAT delivery